Loading...
conference paper
The immunocytokine PD1-IL2v overcomes immune checkpoint resistance, and combination with an anti-PD-L1 antibody further enhances its anti-tumor activity.
July 1, 2021
Cancer Research
Use this identifier to reference this record
Type
conference paper
Web of Science ID
WOS:000680263502022
Authors
•
•
Codarri-Deak, Laura
•
Umana, Pablo
•
Klein, Christian
•
Publication date
2021-07-01
Publisher
Published in
Cancer Research
Publisher place
Philadelphia
Volume
81
Issue
13
Subjects
Peer reviewed
REVIEWED
EPFL units
Available on Infoscience
September 11, 2021